BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 25757623)

  • 1. Aptamer-siRNA chimeras for HIV.
    Takahashi M; Burnett JC; Rossi JJ
    Adv Exp Med Biol; 2015; 848():211-34. PubMed ID: 25757623
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of cell-type specific anti-HIV gp120 aptamers for siRNA delivery.
    Zhou J; Li H; Zhang J; Piotr S; Rossi J
    J Vis Exp; 2011 Jun; (52):. PubMed ID: 21730942
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Receptor-targeted aptamer-siRNA conjugate-directed transcriptional regulation of HIV-1.
    Zhou J; Lazar D; Li H; Xia X; Satheesan S; Charlins P; O'Mealy D; Akkina R; Saayman S; Weinberg MS; Rossi JJ; Morris KV
    Theranostics; 2018; 8(6):1575-1590. PubMed ID: 29556342
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual functional RNA nanoparticles containing phi29 motor pRNA and anti-gp120 aptamer for cell-type specific delivery and HIV-1 inhibition.
    Zhou J; Shu Y; Guo P; Smith DD; Rossi JJ
    Methods; 2011 Jun; 54(2):284-94. PubMed ID: 21256218
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selection, characterization and application of new RNA HIV gp 120 aptamers for facile delivery of Dicer substrate siRNAs into HIV infected cells.
    Zhou J; Swiderski P; Li H; Zhang J; Neff CP; Akkina R; Rossi JJ
    Nucleic Acids Res; 2009 May; 37(9):3094-109. PubMed ID: 19304999
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cell-type-specific aptamer and aptamer-small interfering RNA conjugates for targeted human immunodeficiency virus type 1 therapy.
    Zhou J; Rossi J
    J Investig Med; 2014 Oct; 62(7):914-9. PubMed ID: 25118114
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel dual inhibitory function aptamer-siRNA delivery system for HIV-1 therapy.
    Zhou J; Li H; Li S; Zaia J; Rossi JJ
    Mol Ther; 2008 Aug; 16(8):1481-9. PubMed ID: 18461053
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functional in vivo delivery of multiplexed anti-HIV-1 siRNAs via a chemically synthesized aptamer with a sticky bridge.
    Zhou J; Neff CP; Swiderski P; Li H; Smith DD; Aboellail T; Remling-Mulder L; Akkina R; Rossi JJ
    Mol Ther; 2013 Jan; 21(1):192-200. PubMed ID: 23164935
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incorporation of aptamers in the terminal loop of shRNAs yields an effective and novel combinatorial targeting strategy.
    Pang KM; Castanotto D; Li H; Scherer L; Rossi JJ
    Nucleic Acids Res; 2018 Jan; 46(1):e6. PubMed ID: 29077949
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intracellular delivery of RNA-based therapeutics using aptamers.
    Thiel KW; Giangrande PH
    Ther Deliv; 2010 Dec; 1(6):849-61. PubMed ID: 21643487
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Small Interfering RNAs and their Delivery Systems: A Novel Powerful Tool for the Potential Treatment of HIV Infections.
    Bolhassani A; Milani A
    Curr Mol Pharmacol; 2020; 13(3):173-181. PubMed ID: 31760929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aptamer-targeted RNAi for HIV-1 therapy.
    Zhou J; Rossi JJ
    Methods Mol Biol; 2011; 721():355-71. PubMed ID: 21431697
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic potential of aptamer-siRNA conjugates for treatment of HIV-1.
    Zhou J; Rossi JJ
    BioDrugs; 2012 Dec; 26(6):393-400. PubMed ID: 23046156
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An aptamer-siRNA chimera suppresses HIV-1 viral loads and protects from helper CD4(+) T cell decline in humanized mice.
    Neff CP; Zhou J; Remling L; Kuruvilla J; Zhang J; Li H; Smith DD; Swiderski P; Rossi JJ; Akkina R
    Sci Transl Med; 2011 Jan; 3(66):66ra6. PubMed ID: 21248316
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted siRNA delivery using aptamer-siRNA chimeras and aptamer-conjugated nanoparticles.
    Sivakumar P; Kim S; Kang HC; Shim MS
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2019 May; 11(3):e1543. PubMed ID: 30070426
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rabies Prophylactic and Treatment Options: An In Vitro Study of siRNA- and Aptamer-Based Therapeutics.
    Scott TP; Nel LH
    Viruses; 2021 May; 13(5):. PubMed ID: 34064911
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In Silico Selection of Gp120 ssDNA Aptamer to HIV-1.
    Sepehri Zarandi H; Behbahani M; Mohabatkar H
    SLAS Discov; 2020 Oct; 25(9):1087-1093. PubMed ID: 32452249
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current progress of RNA aptamer-based therapeutics.
    Zhou J; Bobbin ML; Burnett JC; Rossi JJ
    Front Genet; 2012; 3():234. PubMed ID: 23130020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Isolation and characterization of 2'-F-RNA aptamers against whole HIV-1 subtype C envelope pseudovirus.
    London GM; Mayosi BM; Khati M
    Biochem Biophys Res Commun; 2015 Jan; 456(1):428-33. PubMed ID: 25482445
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cell-specific RNA aptamer against human CCR5 specifically targets HIV-1 susceptible cells and inhibits HIV-1 infectivity.
    Zhou J; Satheesan S; Li H; Weinberg MS; Morris KV; Burnett JC; Rossi JJ
    Chem Biol; 2015 Mar; 22(3):379-90. PubMed ID: 25754473
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.